VENUS PHARMA
Pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer with human-health and veterinary product divisions and a portfolio spanning tablets, capsules, injectables and other dosage forms.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer
- Address
- 23 KM, Multan Road, Lahore 54000, Pakistan · 54000
- Website
- venuspharma.net ↗
- Phone
- +92 42 35966651; +92 42 36300875
- info@venuspharma.net
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Matamax | Metoclopramide | 10 mg | Tablet | 1x500 jar pack | 028335 | PKR 583.94 | — | No comparator |
| Matamax | Metoclopramide | 10 mg | Tablet | 10x10 | 028335 | PKR 135.80 | PKR 1.36/tablet | 40% below median |
| Matamex | Metoclopramide | 5 mg | Injection | 1x2ml amps | 012087 | PKR 30.96 | — | No comparator |
| Metovine | Metronidazole + Diloxanide furoate | 400 mg + 500 mg | Tablet | 3x5,s | 028312 | PKR 100.49 | PKR 6.70/tablet | 28% below median |
| Metrove | Metronidazole (Benzoate) | 5 mg | Injection | 100ml | 027973 | PKR 105.92 | PKR 1.06/mL | No comparator |
| Metrove | Metronidazole (Benzoate) | 200 mg | Tablet | 1x500 jar pack | 028333 | PKR 543.19 | — | No comparator |
| Metrove | Metronidazole (Benzoate) | 200 mg | Tablet | 10x10 | 028333 | PKR 135.80 | PKR 1.36/tablet | 23% below median |
| Metrove | Metronidazole (Benzoate) | 400 mg | Tablet | 1x250 jar pack | 028334 | PKR 407.39 | — | No comparator |
| Metrove | Metronidazole (Benzoate) | 400 mg | Tablet | 10x10 | 028334 | PKR 203.70 | PKR 2.04/tablet | 34% below median |
| Midazocine | Midazolam | 1 mg | Injection | 5ml x 5’s | 097634 | PKR 353.07 | PKR 14.12/mL | No comparator |
| Mikacin | Amikacin | 100 mg | Injection | 2mlx1’s | 057357 | PKR 55.68 | PKR 27.84/mL | 35% below median |
| Mikacin | Amikacin | 250 mg | Injection | 2mlx1’s | 057358 | PKR 89.62 | PKR 44.81/mL | 32% below median |
| Mikacin | Amikacin | 500 mg | Injection | 2mlx1’s | 057359 | PKR 169.74 | PKR 84.87/mL | 30% below median |
| Ondansetron | Ondansetron | 8 mg/4 mL | Injection | 5'sx4ml | 121593 | PKR 3,926.16 | PKR 196.31/mL | 22% below median |
| Oxytocin | Oxytocin | 5 IU | Injection | 50's ampoules | 124530 | PKR 759.41 | PKR 15.19/vial/unit | No comparator |
| Phenobarbital | Phenobarbital | 30 mg | Tablet | 1000's | 057350 | PKR 499.73 | PKR 0.50/tablet | 44% below median |
| Phenobarbital | Phenobarbital | 30 mg | Tablet | 100’s | 057350 | PKR 153.40 | PKR 1.53/tablet | 71% above median |
| Phenobarbital | Phenobarbital | 200 mg/mL | Injection | 1mlx50’s | 098312 | PKR 568.99 | PKR 11.38/mL | 18% below median |
| Phenobarbital | Phenobarbital | 200 mg/mL | Injection | 1mlx5’s | 098312 | PKR 57.03 | PKR 11.41/mL | 18% below median |
| Polyvee Ointment | Polymyxin B + Bacitracin | 10000 units/g + 500 units/g | Ointment | 20gm | 019335 | PKR 65.18 | PKR 3.26/g | Near median |
| Polyvee Ointment | Polymyxin B + Bacitracin | 10000 units/g + 500 units/g | Ointment | 10gm | 019335 | PKR 32.59 | PKR 3.26/g | Near median |
| Protic | Neostigmine methylsulfate | 0.5 mg | Injection | 1mlx5's | 040574 | PKR 74.69 | PKR 14.94/mL | No comparator |
| Quinine | Quinine dihydrochloride | 300 mg | Injection | 2ml | 013620 | PKR 71.45 | PKR 35.73/mL | No comparator |
| Quinine Bisulphate | Quinine bisulfate | 300 mg | Tablet | 100's | 028336 | PKR 271.60 | PKR 2.72/tablet | Near median |
| Quinine Bisulphate | Quinine bisulfate | 300 mg | Tablet | 10x10 | 028336 | PKR 291.97 | PKR 2.92/tablet | 8% above median |
| Quinine Bisulphate | Quinine bisulfate | 300 mg | Tablet | 200's | 028336 | PKR 543.19 | PKR 2.72/tablet | Near median |
| Spinocaine | Bupivacaine | 5 % | Injection | 5mlx10's | 040575 | PKR 129.01 | PKR 2.58/mL | No comparator |
| Threesil | Magnesium trisilicate + Aluminium hydroxide | 500 mg + 250 mg | Tablet | 1x1000 jar pack | 028329 | PKR 162.96 | — | No comparator |
| Threesil | Magnesium trisilicate + Aluminium hydroxide | 500 mg + 250 mg | Tablet | 50x10 | 028329 | PKR 203.70 | PKR 0.41/tablet | No comparator |
| Umiaro 2500Source observed | Lopinavir … | 50 mg | Tablet | 120's | 106008Official source ↗ | No indexed price | — | — |
| Valron | Diclofenac | 25 mg | Injection | 10x3ml | 012092 | PKR 340.58 | PKR 11.35/mL | No comparator |
| Valron | Diclofenac | 25 mg | Injection | 1x100x3ml | 012093 | PKR 3,096.19 | — | No comparator |
| Valron | Diclofenac | 50 mg | Tablet | 1x200 jar pack | 028332 | PKR 339.50 | — | No comparator |
| Valron | Diclofenac | 50 mg | Tablet | 2x10 | 028332 | PKR 67.90 | PKR 3.40/tablet | 39% below median |
| Valron | Diclofenac | 50 mg | Tablet | 10x10 | 028332 | PKR 298.76 | PKR 2.99/tablet | 46% below median |
| Valron-100 SR | Diclofenac | 100 mg | Tablet | 3x10's | 078833 | PKR 187.40 | PKR 6.25/tablet | 8% below median |
| Valron-100 SR | Diclofenac | 100 mg | Tablet | 10’s | 078833 | PKR 67.90 | PKR 6.79/tablet | 9% above median |
| Varax | Ephedrine | 10 mg | Tablet | 1x100 jar pack | 028323 | PKR 100.49 | — | No comparator |
| Varax | Ephedrine | 10 mg | Tablet | 10x10 | 028323 | PKR 135.80 | PKR 1.36/tablet | No comparator |
| Vee-Bufen | Ibuprofen | 400 mg | Tablet | 250 | 028308 | PKR 579.21 | PKR 2.32/tablet | 34% below median |
| Vee-Bufen | Ibuprofen | 400 mg | Tablet | 25x10 | 028308 | PKR 632.05 | PKR 2.53/tablet | 28% below median |
| Vee-Bufen | Ibuprofen | 200 mg | Tablet | 1x500's | 028328 | PKR 708.51 | PKR 1.42/tablet | 39% below median |
| Vee-Bufen | Ibuprofen | 200 mg | Tablet | 50x10's | 028328 | PKR 753.87 | PKR 1.51/tablet | 35% below median |
| Veebufen Comp | Ibuprofen | 200 mg | Tablet | 10x10 | 063114 | PKR 258.02 | PKR 2.58/tablet | 14% above median |
| Veebufen Comp. Forte | Ibuprofen | 400 mg | Tablet | 10x10 | 063115 | PKR 661.58 | PKR 6.62/tablet | 89% above median |
| Veerium | Atracurium besylate | 50 mg/5 mL | Injection | 5'sx5ml | 124531 | PKR 377.23 | PKR 15.09/mL | 70% below median |
| Vegamet -200 | Cimetidine | 200 mg | Tablet | 1x200's | 028319 | PKR 366.66 | PKR 1.83/tablet | 13% below median |
| Vegamet -200 | Cimetidine | 200 mg | Tablet | 2x10 | 028319 | PKR 47.53 | PKR 2.38/tablet | 29% above median |
| Vegamet -200 | Cimetidine | 200 mg | Tablet | 20x10 | 028319 | PKR 369.37 | PKR 1.85/tablet | 12% below median |
| Vegamet – 400 | Cimetidine | 400 mg | Tablet | 10x10 | 028320 | PKR 332.70 | PKR 3.33/tablet | 20% below median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.